CELLSCRIPT

Executive Summary

CELLSCRIPT, founded in 1995 and headquartered in Madison, Wisconsin, is a specialized biotechnology company providing critical reagents and systems for RNA research and development. The company's core technologies encompass mRNA synthesis, capping, polyadenylation, and quality control, serving the life science research, diagnostics, and therapeutic mRNA development sectors. As a key enabler of mRNA-based innovations, CELLSCRIPT's tools are essential for producing high-quality, stable, and low-immunogenicity mRNA, which underpins modern RNA therapeutics and vaccines. The company's long-standing presence and deep expertise position it as a reliable partner in the rapidly evolving RNA landscape. Looking forward, CELLSCRIPT is poised to benefit from the continued growth of mRNA therapeutics, including personalized cancer vaccines and rare disease treatments. The company's focus on improving mRNA purity and reducing immunogenicity aligns with industry demands for safer and more effective RNA medicines. Additionally, expansions into diagnostics and emerging RNA modalities like circular RNA present new avenues for growth. With a robust product portfolio and established reputation, CELLSCRIPT is well-positioned to capture incremental market share, though its mature status implies more moderate growth compared to earlier-stage biotechs.

Upcoming Catalysts (preview)

• Q3 2026Launch of Advanced mRNA Capping Technology80% success
• H2 2026Strategic Partnership with Major mRNA Therapeutics Developer50% success
• 2027Expansion into RNA Editing Tool Market40% success